The FDA has approved a new freeze-dried formulation of Jynneos (smallpox and mpox vaccine, live, non-replicating).

Denmark's Bavarian Nordic said on Monday the U.S. Food and Drug Administration has approved a freeze-dried formulation of its mpox and smallpox vaccine. The company said the newly approved formulation ...

A recent study has shown that one dose of Bavarian Nordic’s Jynneos vaccine was overall 58% effective at preventing mpox infection.

A new report from GlobalData has raised concerns over the effectiveness of mpox vaccines for people living with HIV. Findings from a recent study published in The Lancet Infectious Diseases show that ...

Marketed as Jynneos in the US, the vaccine currently exists in a liquid-frozen formulation. These products require a temperature-controlled supply chain that keeps them frozen between production ...

Bavarian Nordic said it was contracted by the U.S Biomedical Advanced Research and Development Authority to develop and supply the freeze-dried version of Jynneos for stockpiling.